F.D.A. Updates Recall of Tomatoes, Warning of a High Risk of Illness or Death
The Food and Drug Administration has updated an ongoing recall of tomatoes distributed in three states to its most severe warning, saying there is a higher probability that potential salmonella contamination could lead to 'serious adverse health consequences or death.'
It is unlikely that consumers will encounter any fresh tomatoes from the recalled batch, but the bacteria can survive for weeks in dry environments and months in wet ones, such as the freezer, according to the F.D.A.
The tomatoes, which were sold in packages as small as a three-pack and as large as 25 pounds, were distributed between April 23 and 28 to Georgia, North Carolina and South Carolina under the name H&C Farms Label.
They were first voluntarily recalled at the beginning of May for possible salmonella contamination. No illnesses were reported at the time, according to the F.D.A.
The recall was updated on Wednesday to Class I, which the F.D.A. describes as 'a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.'
The potential source of contamination was not immediately known. Williams Farms Repack, the South Carolina-based firm that distributed the tomatoes, did not immediately respond to a request for comment on Saturday. H&C Farms declined to comment on Saturday.
Exposure to salmonella, a bacteria, can be deadly, especially in adults over 65, children under 5 and people with compromised immune systems, who have the highest risk of severe illness.
But healthy people should also avoid eating the tomatoes.
Exposure to salmonella, usually from contaminated foods, sickens more than one million people in the United States each year and it is responsible for more than 400 deaths annually.
The infection caused by salmonella can trigger symptoms including fever, diarrhea and abdominal pain that may last for days.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS
SUZHOU, China, June 2, 2025 /PRNewswire/ -- XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received seven Investigational New Drug (IND) approvals for registered clinical trials from both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA). All approvals focus on clinical-grade, off-the-shelf and allogeneic iPSC-derived cell therapy candidates targeting central nervous system (CNS) diseases with significant unmet medical needs, including: Parkinson's Disease (PD), the world's second most prevalent neurodegenerative disease affecting over 10 million patients globally (Phase I clinical trials in both China and the U.S.); Spinal Cord Injury (SCI), a major CNS disease impacting more than 10 million patients globally (First-in-Class; Phase I clinical trials in China and the U.S.); and Amyotrophic lateral sclerosis (ALS), a devastating rare neurodegenerative disease (First-in-Class; Phase I/II clinical trial in China and Phase I in the U.S.; designated as an Orphan Drug by the U.S. FDA). XellSmart has completed multiple cases of iPSC-derived dopaminergic neural progenitor cell therapy for patients with Parkinson's disease, including"the first case"in China. This clinical study was approved by the National Health Commission (NHC) of China. In the clinical study, clinical-grade iPSC-derived dopaminergic neural progenitor cells were transplanted into the putamen of the striatum in patients with moderate to advanced Parkinson's disease. With follow-up periods exceeding 12 months, no cell therapy-related adverse events have been observed. Multiple patients showed significant improvements in key efficacy indicators, including"on/off"time duration and MDS-UPDRS scores, as well as notable enhancements in non-motor symptoms. XellSmart is committed to developing clinical-grade, off-the-shelf allogeneic iPSC-derived cell therapies targeting central nervous system (CNS) diseases with no effective treatment options. XellSmart is at the forefront of advancing innovative iPSC-based therapies to address major and intractable CNS disorders:In 2023, China's first iPSC-derived cell therapy (XS228 injection), developed by XellSmart, was granted by FDA as Orphan Drug Designation (ODD) for the treatment of amyotrophic lateral sclerosis (ALS). In 2024, China's first national-level registered clinical study of an iPSC-derived cell therapy for Parkinson's disease—also developed by XellSmart—was approved and initiated, including the first case treated in China. In 2024, the world's first national-level registered clinical study of a subtype-specific iPSC-derived neural progenitor cell therapy (XS228 injection) for ALS was approved. Multiple patients, including the world's first ALS case treated with this approach, received therapy with good safety profiles and preliminary data showing slowed disease progression. In 2025, China's first registrational Phase I clinical trial of an off-the-shelf allogeneic iPSC-derived dopaminergic neural progenitor cell therapy (XS411 injection) for Parkinson's disease was launched, led by the National Neurological Disease Medical Center at Beijing Tiantan Hospital. In 2025, China's first randomized, double-blind, controlled Phase I/II clinical trial of XS411 injection was initiated to treat early-onset Parkinson's disease (EOPD), led by Huashan Hospital of Fudan University, a National Neurological Disease Medical Center. In 2025, the world's first registrational Phase I clinical trial of an off-the-shelf, allogeneic iPSC-derived subtype-specific neural progenitor cell therapy was launched by The Third Affiliated Hospital of Sun Yat-sen University, targeting spinal cord injury (SCI) — a major neurological disorder with no effective treatment. In 2025, the world's first Phase I/II registrational clinical trial of XS228 injection—an off-the-shelf, allogeneic iPSC-derived subtype-specific neural progenitor cell therapy—was initiated by Peking University Third Hospital, targeting ALS, a devastating rare neurodegenerative disease. XellSmart has established a fully dedicated, internationally competitive "All-In" team focusing on development of clinical-grade, allogeneic, off-the-shelf iPSC-derived cell therapies for central nervous system (CNS) diseases that currently lack effective treatment options. XellSmart has built a portfolio of proprietary, globally leading industrial technologies and platforms, fueling sustained in-house innovation centered on its core business. To develop iPSC-derived cell therapy candidates, XellSmart has established and operates an R&D center, a B+ and A-grade GMP manufacturing facility, and a quality control center spanning over 5,000 square meters. Multiple clinical-grade iPSC-derived cell therapy candidates developed by XellSmart have completed core CMC development, with fully integrated clinical-grade manufacturing processes and quality control systems in place. XellSmart has successfully produced clinical batches of multiple GMP-grade iPSC-derived subtype-specific neural progenitor cell therapies, currently deployed in multiple clinical trials. XellSmart has secured multiple rounds of financing, collectively led by renowned market-driven venture capital firms including Qiming Venture Partners, Eli Lilly Asia Ventures, Sequoia Capital China (Hongshan), and others. View original content: SOURCE XellSmart Sign in to access your portfolio
Wall Street Journal
an hour ago
- Wall Street Journal
How Moderna Went From Pandemic Hero to Vaccine Victim
Moderna MRNA 1.84%increase; green up pointing triangle was once a darling of the first Trump administration, which went to great lengths to help the company develop its Covid-19 vaccine that protected millions of people from the virus. Now the biotech is caught in the crossfire of Trump 2.0 as vaccine-making comes under fire. In the latest setback for Moderna MRNA 1.84%increase; green up pointing triangle, the Food and Drug Administration on Friday approved its next-generation Covid shot for a narrower population of patients than the company intended. The approval grants use of the vaccine only in older adults and people aged 12 to 64 with health risks.
CBS News
an hour ago
- CBS News
How a minor league ballpark revived a struggling downtown in South Carolina
For Greenville, South Carolina, Fluor Field is a field of dreams come true. The stadium is home to the Greenville Drive, the High-A Minor League Baseball team for the Boston Red Sox, complete with a replica of Fenway Park's Green Monster — the popular nickname for its massive, left field wall. But its big pitch is community. "We were really embraced by the community, and then we began to learn all that a baseball team can do for a community," said Craig Brown, a former high-powered Manhattan advertising executive who built the stadium for $20 million in 2006. Brown still owns the stadium and the team. "Fluor Field has become the front porch of the community. In the South, the front porch is where the family gathers. That's very much how we operate the place," Brown told CBS News. The ballpark has had a monster impact on the local economy. It draws roughly half a million people a year for ball games and other events. Over the last decade, the city says the team's financial impact has been nearly $300 million. But the stadium did much more. After a number of Greenville textile factories shuttered, Fluor Field — using bricks salvaged from demolished mills — jump-started a renaissance in the city's West End downtown, a blighted area that used to be viewed as seedy and scary. "There was a letter to the editor that said, you put a baseball stadium down there, only prostitutes will go to baseball games," Greenville Mayor Knox White said. White has been the city's mayor for 30 years. He says Greenville's approach 20 years ago was unusual for the time, but savvy. The city insisted that the downtown stadium be part of an ambitious, mixed-use development. "This was the transformational event. Suddenly, this area close into the stadium became a place for condos and some high rises and hotels. But beyond it, residential neighborhoods were transformed, as well," White said. The mixed-use approach draws people and new businesses downtown. Old Europe Desserts serves coffee and sweets several blocks from the ballpark. When asked why the baseball stadium was such a big draw, owner Bobby Daugherty said, "Bodies. I sell cake. I need bodies through the door. So I knew [it] was kinda right in the middle of all the traffic, if you will." It's symbolic of what Greenville found here: a sweet spot for development that touches all the bases.
